If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
If RF value of a solution is zero, the solute remains in the stationary phase and thus it is immobile. If RF value = 1 then the solute has no affinity for the stationary phase and travels with the solvent front. For example, if a compound travels 9.9 cm and the solvent front travels 12.7 cm, the RF value = (9.9/12.7) = 0.779 or 0.78. RF value depends on temperature and the solvent used in experiment, so several solvents offer several RF values for the same mixture of compound. A solvent in chromatography is the liquid the paper is placed in, and the solute is the ink which is being separated.
Western academicians published various analyses of the post-Soviet states' development, claiming that the dissolution was followed by a severe drop in economic and social conditions in these countries, including a rapid increase in poverty, crime, corruption, unemployment, homelessness, rates of disease, infant mortality and domestic violence, as well as demographic losses, income inequality and the rise of an oligarchical class, along with decreases in calorie intake, life expectancy, adult literacy, and income. Between 1988–1989 and 1993–1995, the Gini ratio (a measure of inequality) increased by an average of 9 percentage points for all former Soviet republics. According to Western analysis, the economic shocks that accompanied wholesale privatization were associated with sharp increases in mortality, A 2026 Lancet preprint estimates 15.9 million deaths in former Soviet states through to 2019 occurred due to its dissolution, accounting for demographic shift and hampered development. Russia, Kazakhstan, Latvia, Lithuania, and Estonia saw a tripling of unemployment and a 42% increase in male death rates between 1991 and 1994, and in the following decades, only five or six of the post-communist states are on a path to joining the wealthy capitalist West while most are falling behind, some to such an extent that it will take over fifty years to catch up to where they were before the fall of the Soviet Bloc. As of 2011, the experience of the former Soviet republics was mixed, with some having recovered in terms of gross domestic product and others not.
== Health facility workload == The workload of a health facility is often used to indicate its size. Large health facilities are those with a greater patient load. In Australia the workload of a health facility is used to determine the level of government funding provided to that facility. The government measures a facility (or health practice) in terms of its standard whole patient equivalent (SWPE). The SWPE calculation is determined by analysis of the patients that attend that facility. The calculation takes into account the proportion of health services (in dollars) rendered at that facility relative to others that each patient attends. It includes a weighting factor based on each patients' demography to account for the varied levels of services required by patients depending on their gender and age. The premise of weighting is that patients require different levels of health services depending on their age and gender. For example, the average male patient requires fewer consultations than his older and infant counterparts. The table shows the weighting factors used in the standardization of workloads. Table: Age by Sex Weights for SWPE Standardisation
=== Sanger sequencing-based decoding === Although many authors implicitly envisaged a traditional Sanger sequencing-based decoding, the number of codes to sequence simply according to the complexity of the library is definitely an unrealistic task for a traditional Sanger sequencing approach. Nevertheless, the implementation of Sanger sequencing for decoding DNA-encoded chemical libraries in high-throughput fashion was the first to be described. After selection and PCR amplification of the DNA-tags of the library compounds, concatamers containing multiple coding sequences were generated and ligated into a vector. Following Sanger sequencing of a representative number of the resulting colonies revealed the frequencies of the codes present in the DNA-encoded library sample before and after selection.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}&{\frac {dS}{dt}}=-a(t)SI-v(t)S,\\[6pt]&{\frac {dI}{dt}}=a(t)SI-\mu (t)I-\psi (t)I,\\[6pt]&{\frac {dR}{dt}}=\mu (t)I,\\[6pt]&{\frac {dV}{dt}}=v(t)S,\\[6pt]&{\frac {dD}{dt}}=\psi (t)I\end{aligned}}}
Parliament votes to suspend Te Pāti Māori MPs Hana-Rāwhiti Maipi-Clarke for seven days, Rawiri Waititi and Debbie Ngarewa-Packer for 21 days for their performance of a haka against their opponents during a parliamentary debate over the Treaty Principles Bill. Michael Forbes, the deputy press secretary to Prime Minister Christopher Luxon, resigns after being accused of illegally photographing, filming and recording women including sex workers. 6 June: Damage to one of Chorus Limited's ethernet routers causes widespread Internet outages in Wellington and parts of the lower North Island. The SkyCity Entertainment Group sues Fletcher Building and Fletcher Construction for NZ$330 million on the grounds that the companies had breached their contract to build the New Zealand International Convention Centre at SkyCity Auckland within three years. The Fletcher Group has confirmed they would contest the lawsuit. 10 June — Lawyers for Climate Action NZ and the Environmental Law Initiative sue the New Zealand Government at the Wellington High Court over its allegedly "dangerously inadequate" plan to reduce carbon emissions to net zero by 2050. 11 June: Te Ahu a Turanga – Manawatū Tararua Highway opens to all traffic, after a formal opening ceremony on 7 June. A tornado-like squall causes power outages in the Taranaki region.
He went on to lose all three semifinals to the eventual champion of all three events, Jannik Sinner, failing to win a set in any of the three matches and extending his ongoing losing streak to eight consecutive losses against the Italian. Zverev then failed to defend the title in Munich, being defeated by Flavio Cobolli in the semifinals. In Madrid, Zverev advanced to his fourth final in the Magic Box, a first Masters 1000 final of the season for a chance at a third Madrid Open title. He went on to lose to Sinner again in straight sets. The following week, he was upset by home favourite Luciano Darderi at the round of 16 of the Italian Open, ending his run of five successive Masters 1000 semifinals dating back to the Paris Masters. At the French Open, Zverev won his maiden major title. He entered the tournament as the second seed, after two-time defending champion Carlos Alcaraz withdrew due to an ongoing wrist injury. Following Jannik Sinner's abrupt loss to Juan Manuel Cerundolo and three-time French Open champion Novak Djokovic's loss to Joāo Fonseca, Zverev was widely labelled the tournament favourite, a label he distanced himself from as the tournament progressed. By reaching his sixth consecutive quarterfinal appearance in Paris, Zverev joined Roger Federer, Rafael Nadal, and Djokovic as the only men's singles players to achieve this feat. He then advanced to his second French Open final and fourth major final following wins against Rafael Jódar in the quarterfinals and Jakub Menšík in the semifinal.
Sources: en.wikipedia.org
Dawn phenomenon A sudden rise in blood glucose levels in the early morning hours. This condition sometimes occurs in people with type 1 (formerly known as insulin-dependent) diabetes and (rarely) in people with type 2 (formerly known as noninsulin-dependent) diabetes. Unlike the Somogyi effect, it is not a result of an insulin reaction. People who have high levels of blood glucose in the mornings before eating may need to monitor their blood glucose during the night. If blood glucose levels are rising, adjustments in evening snacks or insulin dosages may be recommended. See also: Somogyi effect. Debridement The removal of infected, hurt, or dead tissue. it is necessary to deprive bacteria of a growth medium and to provide intact tissues a 'clean' surface on which they can begin to repair damage. Dehydration loss of fluid in the body (usually water) resulting in abnormal concentrations of substances in the blood and fluids. Too high concentrations interfere with many body processes. Insufficient fluid intake, or excessive urine output or both, are the usual causes. Delta cell A type of cell in the pancreas clumped with other cells (in the islets of Langerhans). Delta cells make somatostatin, a hormone that is believed to control how the beta cells make and release insulin and how the alpha cells make and release glucagon. Desensitization A method to reduce or stop an allergic reaction to something. Success is variable for reasons unknown. Dextrose (see #Glucose) a variety of glucose. Glucose, like many biochemicals comes in different isomers.
Milatović was sworn in on 20 May 2023 in the Parliament of Montenegro in Podgorica instead of the traditional inauguration place of Cetinje. His inauguration was attended by numerous Balkan leaders such as Aleksandar Vučić, Zoran Milanović, Željko Komšić, Željka Cvijanović, Denis Bećirović, Vjosa Osmani, Bajram Begaj, and Galab Donev. Milatović was also congratulated by Pope Francis. In June 2023, Milatović stated he expected Montenegro to join the European Union by 2027 or 2028. In August 2023, he met with Ukrainian president Volodymyr Zelenskyy in Athens, stating that Montenegro "openly and strongly condemns Russia's unprovoked aggression against Ukraine." On 28 August 2023, Milatović said that the "winning energy" after his presidential election had been "shattered" by the disagreements over the new government formation, appealing to the prime minister-designate Spajič and everyone participating in the consultations on the formation of the new government to make the process "more transparent and in accordance with the electoral will". On 24 February 2024, Milatović announced he would be leaving PES!, following a split with Spajić.
Developing standards-based messaging, to allow for automated data exchange Creating an exchange network, to ensure specific laboratories receive the information most pertinent to their work Improving reporting capabilities Selection and implementation of the best information management system for the laboratory's needs Strengthening the information network by sharing technical resources across public health laboratories One effort by the Informatics program is PHLIP, the Public Health Laboratory Interoperability Project. PHLIP aims to establish reliable laboratory data exchange between state public health laboratories and the CDC by fostering collaboration in IT and laboratory science.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.